Hosted on MSN1mon
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
Besides osteosarcoma, GSK is also developing GSK’227 for treating extensive-stage small-cell lung cancer (ES-SCLC), an aggressive and difficult-to-treat cancer. Last month, the European ...
pharmaphorum1d
GSK bags breakthrough status for bone cancer drug
The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma ... or refractory extensive-stage small-cell lung cancer (SCLC), with the ...
Pharmabiz1mon
US FDA grants breakthrough therapy designation to GSK’s B7-H3-targeted ADC, GSK’227 to treat relapsed or refractory osteosarcoma
For patients with relapsed or refractory osteosarcoma, there is an urgent unmet medical need ... and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies.